Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Transitional Cell

Metastatic Urothelial Cancer

Urothelial Bladder Carcinoma

Salivary Gland Neoplasms

Neoplasm Metastasis

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Breast Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Lung Neoplasms, Small Cell Lung Carcinoma

Breast Neoplasms

Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Glioblastoma

Salivary Gland Neoplasms, Thyroid Neoplasms

Breast Neoplasms

Carcinoma, Transitional Cell

Lung Neoplasms

Prostatic Neoplasms

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

VELOCITY-Lung

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

TROPHY U-01

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

EVOKE-02

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

TROPiCS-03

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

SATROPIN

STORM

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

SERIES

PRIMED

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Scalp Cooling in MBC

Study of Sacituzumab Govitecan in Patients With Solid Tumor

ELEVATE TNBC

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

NeoSTAR

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Sacituzumab Govitecan in Recurrent Glioblastoma

TROP2

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

InCITe

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy